Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gene Logic to change its name to Ore Pharmaceuticals
This request for approval will be accompanied by a proxy proposal, also approved by the board, to sell the company’s genomics assets to Ocimum Biosolutions. Ownership of the
This request for approval will be accompanied by a proxy proposal, also approved by the board, to sell the company’s genomics assets to Ocimum Biosolutions. Ownership of the
The offer price represents an approximate 32% premium over the 10-day average closing price per share for E-Z-EM as of October 29, 2007, the last trading day prior
The Phase I study is designed to evaluate the safety, tolerability, and pharmacokinetics of the HIF-1 alpha antagonist in a daily for five days schedule. Hypoxia-inducible factor-1 alpha
The marketing authorization application is based on data from three Phase III studies of rivaroxaban in the prevention of venous thromboembolism after major orthopedic surgery of the lower
The multi-center, prospective randomized Phase III clinical trial is expected to enroll approximately 100 evaluable children with hepatoblastoma, an orphan disease, being treated with cisplatin. Patients will be
Javelin views the UK Dyloject approval as an attractive opportunity to inaugurate its European Dyloject franchise. Javelin’s UK marketing authorization is the first step in securing distribution and
According to the license agreement, Foamix has the exclusive rights to use the dual-chamber device for all topical and intra-vaginal drug products requiring prescription. The device is protected
Bio-Trials provides clinical monitoring, clinical site coordination, regulatory support, study management and supply distribution services. Jeff Thomis, president of global clinical development services for Quintiles, said: “The acquisition
In rulings on the admissibility of plaintiff’s expert testimony and on the motion for summary judgment, the court found that the plaintiff, Patricia Zandi, had not offered any
The trial will evaluate the drug’s ability to reduce the incidence of actinic keratosis (AK) and irreversible skin damage in immune-compromised organ transplant patients. The primary endpoint is